Last $7.05 USD
Change Today +0.11 / 1.59%
Volume 43.8K
ICAD On Other Exchanges
Symbol
Exchange
NASDAQ CM
As of 8:10 PM 07/11/14 All times are local (Market data is delayed by at least 15 minutes).

icad inc (ICAD) Snapshot

Open
$6.97
Previous Close
$6.94
Day High
$7.19
Day Low
$6.90
52 Week High
01/16/14 - $14.11
52 Week Low
10/1/13 - $5.16
Market Cap
100.3M
Average Volume 10 Days
48.6K
EPS TTM
$-0.52
Shares Outstanding
14.2M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for ICAD INC (ICAD)

Related News

No related news articles were found.

icad inc (ICAD) Related Businessweek News

No Related Businessweek News Found

icad inc (ICAD) Details

iCAD, Inc. provides image analysis, workflow solutions, and radiation therapy for the early identification and treatment of cancer. The company operates in two segments, Cancer Detection and Cancer Therapy. It offers electronic brachytherapy products (eBx), including Axxent eBx systems for the treatment of early stage breast cancer, endometrial cancer, and non-melanoma skin cancer, as well as for the treatment of other cancers or conditions where radiation therapy is indicated, including intraoperative radiation therapy. The company also provides digital and magnetic resonance imaging (MRI) computer-aided detection (CAD) products, such as SecondLook systems that detect and identify suspicious masses and micro-calcifications; and PowerLook Advanced Mammography Platform, a computer server residing on a customer’s network that receives patient studies from the imaging modality, performs CAD analysis, and sends the CAD results to picture archiving and communication system and/or review workstations. In addition, it offers advanced image analysis and workflow solutions in MRI imaging; and advanced image analysis and workflow solutions in computed tomography (CT) colonography, including VeraLook that supports the detection of colonic polyps in conjunction with CT colonography. Further, the company provides film based products, such as TotalLook MammoAdvantage system, which is a second generation mammography specific digitizer that converts prior mammography films to digital images. iCAD, Inc. primarily serves hospitals, ambulatory care centers and free standing radiation oncology facilities, and other office-based uses. The company sells its products directly, as well as through various original equipment manufacturer partners, distributors, and resellers worldwide. It has strategic partnership agreement with Invivo Corporation. The company was founded in 1984 and is headquartered in Nashua, New Hampshire.

102 Employees
Last Reported Date: 03/3/14
Founded in 1984

icad inc (ICAD) Top Compensated Officers

Chief Executive Officer, President and Direct...
Total Annual Compensation: $412.4K
Chief Operating Officer
Total Annual Compensation: $328.6K
Senior Vice President of Marketing and Strate...
Total Annual Compensation: $253.6K
Compensation as of Fiscal Year 2013.

icad inc (ICAD) Key Developments

iCAD, Inc. Presents at 15th Annual B. Riley & Co. Investor Conference, May-19-2014 04:30 PM

iCAD, Inc. Presents at 15th Annual B. Riley & Co. Investor Conference, May-19-2014 04:30 PM. Venue: Loews Santa Monica Beach Hotel, 1700 Ocean Avenue, Santa Monica, CA 90401, United States. Speakers: Kenneth M. Ferry, Chief Executive Officer, President and Director.

iCAD, Inc. Reports Unaudited Consolidated Earnings Results for the First Quarter Ended March 31, 2014

iCAD, Inc. reported unaudited consolidated earnings results for the first quarter ended March 31, 2014. For the quarter, the company reported total revenue of USD 8,520,000 compared to USD 7,930,000 a year ago. Loss from operations was USD 460,000 compared to USD 328,000 a year ago. Loss before income tax expense was USD 137,000 compared to USD 717,000 a year ago. Net loss and comprehensive loss was USD 190,000 compared to USD 727,000 a year ago. Basic and diluted loss per share was USD 0.02 compared to USD 0.07 a year ago. Non GAAP adjusted EBITDA was USD 447,000 compared to USD 592,000 a year ago. Non GAAP adjusted net loss was USD 1,326,000 compared to USD 1,158,000 a year ago. Non GAAP adjusted net loss per share was USD 0.12 compared to USD 0.11 a year ago. Net cash used for operating activities was USD 1,665,000 compared to USD 1,169,000 a year ago. Additions to property and equipment were USD 202,000 compared to USD 97,000 a year ago. Total revenue for the first quarter of 2014 increased 7.4% from the first quarter of 2013, reflecting a 32% increase in Therapy revenue partially offset by a 10% decline in Cancer Detection revenue.

iCAD Seeks Acquisitions

iCAD, Inc. (NasdaqCM:ICAD) seeks acquisitions. "In addition, a strong balance sheet puts us in a better position with respect to potential acquisitions and licensing arrangements. We continue to be pleased with our financial and operating performance. We're making progress to advance in many areas of our business and now have an improved financial foundation from which to build on the momentum we have achieved. We're confident that 2014 will be another exciting year of growth for iCAD," said Kevin Burns, iCAD - Executive Vice President Finance and Chief Financial Officer. "I guess, well, what I would answer, Brian, is to say when you're in a large market obviously in the early stage, you're trying to see the market and you're also trying to anticipate growth opportunities that are very insular and very complimentary, very synergistic to that core market. So I just say philosophically the way we look at the business is we want to provide a lot more than just a block that delivers therapy. So that could be a range of software capabilities and services that are beyond the services that we offer today to our sites that all have these varying degrees of needs. So I think we're looking, you know, in a I guess open-minded fashion in how over time we can increase our solution offering, if you will, to the skin market in particular and try to get over our growth from other areas that are very natural relative to the workflow as well as the services that need to be provided. So we're taking a look at the category. I wouldn't say we have completed the evaluation. We're in a kind of real-time assessment mode. But clearly, we're committed to the market. We want to add more to offer in that market. So things like software and services are probably high in our list from an investigation standpoint," said Ken Ferry, iCAD, Chief Executive Officer.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
ICAD:US $7.05 USD +0.11

ICAD Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Hologic Inc $25.70 USD +0.22
Merge Healthcare Inc $2.25 USD 0.00
View Industry Companies
 

Industry Analysis

ICAD

Industry Average

Valuation ICAD Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 2.4x
Price/Book 1.9x
Price/Cash Flow NM Not Meaningful
TEV/Sales 1.4x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ICAD INC, please visit www.icadmed.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.